{"id":"ivermectin-reference","safety":{"commonSideEffects":[{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Mazzotti reaction (fever, lymphadenitis)"}]},"_chembl":{"chemblId":"CHEMBL6067487","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ivermectin is a macrocyclic lactone that selectively binds to invertebrate-specific glutamate-gated chloride ion channels, increasing chloride conductance and hyperpolarizing the cell membrane. This leads to paralysis and death of susceptible parasites. The drug has high selectivity for parasitic channels over mammalian GABA receptors, making it relatively safe for human use.","oneSentence":"Ivermectin binds to glutamate-gated chloride channels in parasitic organisms, causing paralysis and death of the parasite.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:29.806Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Onchocerciasis (river blindness)"},{"name":"Lymphatic filariasis"},{"name":"Strongyloidiasis"},{"name":"Scabies"},{"name":"Lice infestations"}]},"trialDetails":[{"nctId":"NCT05993143","phase":"PHASE3","title":"Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50","status":"TERMINATED","sponsor":"Insud Pharma","startDate":"2021-01-18","conditions":"COVID-19, SARS-CoV-2","enrollment":249},{"nctId":"NCT05477810","phase":"EARLY_PHASE1","title":"Bioequivalence of a Single-dose of 12 mg IVERMECTIN as Orally Disintegrating Mini Tablets Versus a Single-dose of 12 mg Regular IVERMECTIN Tablets in Healthy Adults Under Fasting Conditions","status":"COMPLETED","sponsor":"University Children's Hospital Basel","startDate":"2022-09-13","conditions":"Bioequivalence","enrollment":16},{"nctId":"NCT02795117","phase":"PHASE3","title":"Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2016-05","conditions":"Rosacea","enrollment":486},{"nctId":"NCT04854460","phase":"PHASE1","title":"Bioequivalence Study of Ivermectin From Revemact 6 mg Tablets (Man. by EVA Pharma for Horus for Pharmaceutical Industries, Egypt) and Stromectol 2*3 mg Tablets (Merck Sharp & Dohme B.V., Haarlem, The Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2021-01-28","conditions":"Healthy","enrollment":30},{"nctId":"NCT04106726","phase":"PHASE3","title":"Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea","status":"COMPLETED","sponsor":"Zydus Worldwide DMCC","startDate":"2019-10-17","conditions":"Facial Rosacea","enrollment":525},{"nctId":"NCT03337490","phase":"PHASE3","title":"A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice","status":"COMPLETED","sponsor":"Mayne Pharma International Pty Ltd","startDate":"2017-10-02","conditions":"Head Lice","enrollment":296},{"nctId":"NCT02840461","phase":"PHASE3","title":"Clinical Endpoint Study of Ivermectin 1% Cream","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2016-06","conditions":"Moderate to Severe Papulopustular Rosacea","enrollment":630},{"nctId":"NCT03173742","phase":"PHASE1","title":"Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)","status":"COMPLETED","sponsor":"Insud Pharma","startDate":"2016-03","conditions":"Helminthiasis","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":222,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ivermectin (reference)","genericName":"Ivermectin (reference)","companyName":"Padagis LLC","companyId":"padagis-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ivermectin binds to glutamate-gated chloride channels in parasitic organisms, causing paralysis and death of the parasite. Used for Onchocerciasis (river blindness), Lymphatic filariasis, Strongyloidiasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}